Talus Bioscience, a biotechnology company pioneering Native Regulome Profiling for drug discovery recently announced the launch of the Regulome Early Access Program. The program invites researchers working at the frontier of biology to collaborate with Talus Bio in mapping the dynamic protein-DNA regulatory network.
Through this exclusive program, Talus Bio will partner with a small number of academic and industry research groups to offer free access to Native Regulome Profiling, the first technology capable of measuring the activity of the over 4,000 genome-regulating proteins in their natural cellular context and over time.
The regulome is the cell’s decision-making system. With this program, we’re opening up the tools we use internally to others working on some of the most complex, unsolved questions in biology.
— Alex Federation, PhD, CEO and Co-Founder of Talus Bio
Participants in the Regulome Early Access Program will receive:
- Free Native Regulome Profiling in their system of interest
- Access to Talus Bio’s AI-powered analysis pipeline
- Direct 1-on-1 collaboration with the Talus Bio platform team
All resulting datasets will be open-sourced to the community, accelerating collective progress toward understanding and therapeutically targeting transcriptional regulation.
The program is designed to support groundbreaking work in:
- Pathological gene regulation in disease
- Environmental and chemical perturbation responses
- Synthetic and systems biology
- New frontiers in genome regulation
We believe this is a truly unique technology, and now that we’ve really hit our pace with platform capacity, we want to use some of that throughput to collaborate with the broader scientific community.
— Lindsay Pino, PhD, CTO and Co-Founder of Talus Bio
The launch of the Regulome Early Access Program builds on Talus Bio’s recent momentum, including a recent funding round led by Two Bear Capital, and ongoing development of the company’s flagship technology platform for transcription factor drug discovery.